Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncothyreon has reported encouraging results of PX-478, a small molecule inhibitor of hypoxia inducible factor or HIF-1 alpha in a preclinical model of human lung cancer.
Subscribe to our email newsletter
The study has employed a model of lung cancer in mice, which closely mimics the disease in humans. Treatment with oral PX-478 for five days resulted in significant inhibition of tumor growth, marked reduction in lymph nodes metastases, decreased volume of pleural effusions, and significantly improved survival.
PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha. Enrollment is ongoing in the Phase I dose escalation trial of PX-478 in patients with advanced metastatic cancer and lymphoma. Clinical data from this trial are expected in the second half of 2008.